SM
FRTX

Sabby Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Sabby Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Hold
0
– -$325K – 239
2013
Q2 		– Hold
0
– – – 155

Other funds holding FRTX

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Sabby Management's FRTX Position: Q4 2020 in Review

Sabby Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2020, closing a stake of 16,042 shares — an estimated $652K sold.

Sabby Management first reported a position in FRTX in Q3 2013 and held it in 4 quarters. The position peaked at $727K in Q3 2013. 25 funds tracked by Wall St. Rank hold FRTX as of Q4 2020.

  • Sabby Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Sabby Management sold 16,042 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $652K.
  • Sabby Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2013 and held it in 4 quarters.
  • Sabby Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $727K in Q3 2013.
  • 25 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.